Nutraceutical supplements have long been a part of Tyrell’s wellness regimen, and Pharmagreen’s NutraMax Genomic Supplement is exactly formulated to support continued health in the face of body and mind stresses in everyone’s life, from the top performing athlete to the everyday individual. Pharmagreen’s proprietary blend is unique to the market, a nutrigenomic supplement for the utmost mind and body experience. Nutrigenomics, or nutritional genomics, concerns the relationship between nutrients, diet, and genetic expression. Pharmagreen created this new line of genomic supplements because health and wellness start on the cellular level … NutraMax Genomic Supplement will be available for purchase soon through Shopify, Amazon, other third-party online outlets, and the Company’s own pending online store.
According to
Pharamagreen is currently producing its first supply of NutraMax Genomic Supplement enteric capsules at a cGMP certified production facility in the
Mr.
Mr.
About
Pharmagreen is currently developing its nutraceutical products, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant and fungi genetics, Pharmagreen's transgenic program uses the newest technology available to research and create nutraceutical daily supplements that help with mind and body support. For further information on the Company, and our updated website, please visit www.pharmagreen.ca
Safe Harbor Statement
This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. In particular, factors that could cause actual results to differ materially from those in forward looking statements include: our inability to obtain additional financing on acceptable terms; risk that our products and services will not gain widespread market acceptance; inability to compete with others who provide comparable products; the failure of our technology; the infringement of our technology with proprietary rights of third parties; inability to respond to consumer demands; inability to replace significant customers; seasonal nature of our business. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements. When used in this document, the words "believe," "expect," "anticipate," "estimate," "project," "plan," "should," "intend," "may," "will," "would," "potential," and similar expressions may be used to identify forward-looking statements.
The OTC Markets or any other securities regulatory authority has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release that has been prepared by management.
Contact Information:
www.pharmagreen.ca
Tel: (702) 803 9404
Email: info@pharmagreen.ca
Source:
2022 GlobeNewswire, Inc., source